Drug Channels Acquired by HMP Global
Adam Fein, founder of Drug Channels, said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.
Adam J. Fein, Ph.D.
HMP Global, a healthcare education company, will acquire Drug Channels Institute. Founded in 2006 by Adam J. Fein, Ph.D., Drug Channels is a market intelligence company focused on the pharmaceutical industry. It provides webinars and industry reports on pharmaceutical economic issues and drug supply and distribution. Terms of the agreement were not disclosed.
As part of the integration, Drug Channels leadership will remain in place, with Fein becoming president, Drug Channels Institute, and Paula Fein assuming the role of vice president, business development.
Adam Fein is a well-known thought leader in the pharmaceutical industry providing insight and analysis on drug pricing, pharmacy benefit managers, the specialty drug market, drug reimbursement, and healthcare reform. He is known for his humor in making the industry more accessible for readers.
On a blog post on the Drug Channels website, Adam Fein said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.
HMP produces in person and virtual medical education events and provides news and clinical information for healthcare providers. It produces about 50 journals/websites and 400 events and serves oncology, neurology, psychiatry and behavioral health, gastroenterology, cardiovascular, dermatology and rheumatology.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More
